Skip to main content
Resources › Psychotropics A-Z › Risperidone | Risperdal
Atypical (Second-Generation) Antipsychotic

Risperidone

Risperidone is one of the first atypical antipsychotics, indicated for schizophrenia, bipolar disorder, and autism-related irritability. It has a well-established efficacy and safety profile across multiple age groups and is available in oral and long-acting injectable formulations. It demonstrates potent dopamine D2 and serotonin 5-HT2A receptor antagonism with dose-dependent side effects.

Clinical Overview

Primary Clinical Applications

Risperidone is indicated for schizophrenia in adults and adolescents, bipolar I disorder (manic or mixed episodes), and irritability associated with autism spectrum disorder in children and adolescents. It is often considered a first-line atypical antipsychotic due to its extensive evidence base and availability of multiple formulations.

Mechanism and Clinical Benefits

Risperidone antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors with high affinity, providing antipsychotic efficacy while potentially reducing extrapyramidal side effects compared to typical antipsychotics. It also has activity at alpha-1 adrenergic and histamine H1 receptors, contributing to some side effects.

Clinical Considerations

Risperidone has dose-dependent side effects, with lower doses having fewer extrapyramidal symptoms but higher doses approaching typical antipsychotic side effect profiles. It can cause significant prolactin elevation and metabolic effects. The long-acting injectable formulation improves adherence for maintenance therapy.

Key Clinical Points

Extrapyramidal symptoms are dose-related

At low doses risperidone behaves like an atypical antipsychotic; above roughly 6 mg daily the profile increasingly resembles a typical agent. Staying in the 4 to 8 mg range preserves the advantage.

Highest prolactin elevation in its class

Galactorrhoea, amenorrhoea, and sexual dysfunction follow, and are frequent causes of discontinuation. Prolactin should be checked where symptoms emerge.

Licensed for autism-related irritability from age 5

Weight-based dosing from 0.25 mg daily, range 0.5 to 3 mg. This is a distinct indication from schizophrenia and uses much lower doses.

Three weeks of oral overlap with Consta

The long-acting injectable does not reach therapeutic levels for around three weeks, so oral risperidone must continue throughout. Stopping oral cover early is a recognised cause of relapse.

Start at 0.5 mg twice daily in renal or hepatic impairment

A quarter of the usual adult starting dose, with slow titration. Boxed warnings cover both increased mortality in dementia-related psychosis and suicidality in young patients.

Prescribing Information

Dosing & Administration

Schizophrenia – Adults:

  • Initial: 2 mg daily (1 mg twice daily or 2 mg once daily)
  • Titration: Increase by 1-2 mg daily on day 2, then adjust weekly
  • Range: 4-8 mg daily
  • Maximum: 16 mg daily

Schizophrenia – Adolescents (13-17 years):

  • Initial: 0.5 mg once daily
  • Titration: Increase by 0.5-1 mg daily, adjust every 24+ hours
  • Range: 1-6 mg daily

Bipolar I Disorder – Adults:

  • Initial: 2-3 mg once daily
  • Range: 1-6 mg daily

Autism-Related Irritability (5-17 years):

  • <20 kg: 0.25 mg daily initially, range 0.5-3 mg daily
  • ≥20 kg: 0.5 mg daily initially, range 0.5-3 mg daily

Long-Acting Injectable (Consta):

  • Dose: 25 mg IM every 2 weeks
  • Range: 25-50 mg every 2 weeks
  • Oral overlap: Continue oral risperidone for 3 weeks after first injection

Indications

  • Treatment of schizophrenia (adults and adolescents 13-17 years)
  • Treatment of acute manic or mixed episodes of bipolar I disorder (adults and children 10-17 years)
  • Maintenance treatment of bipolar I disorder
  • Treatment of irritability associated with autism spectrum disorder (children and adolescents 5-17 years)

Contraindications

  • Known hypersensitivity to risperidone or any component
  • No absolute contraindications

Warnings & Precautions

  • Boxed Warning: Increased mortality in elderly patients with dementia-related psychosis; increased suicidal thoughts in children, adolescents, and young adults
  • Hyperprolactinemia: Significant elevation, monitor prolactin levels
  • Metabolic changes: Monitor glucose, lipids, and weight
  • Extrapyramidal symptoms: Dose-related risk
  • Tardive dyskinesia: Risk with long-term use
  • Neuroleptic malignant syndrome: Rare but serious risk
  • Orthostatic hypotension: Monitor blood pressure

Drug Interactions

  • CYP2D6 inhibitors: Increase risperidone levels
  • CYP3A4 inducers: Decrease risperidone levels
  • CNS depressants: Enhanced sedation
  • Antihypertensives: Enhanced hypotensive effects

Adverse Reactions

Common (≥5%):

  • Parkinsonism, akathisia, dystonia, tremor
  • Somnolence, dizziness, constipation, nausea
  • Weight gain, fatigue, dry mouth

Endocrine:

  • Hyperprolactinemia, galactorrhea, amenorrhea

Special Populations

  • Renal/Hepatic Impairment: Start with 0.5 mg twice daily, titrate slowly
  • Elderly: Increased mortality risk in dementia-related psychosis
  • Pregnancy: Category C – use only if benefits outweigh risks
  • Pediatric: Monitor growth and development
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.